| 1 |
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC [J]. Eur Heart J, 2021, 42(5): 373-498.
|
| 2 |
Cegla J, Neely R, France M, et al. HEART UK consensus statement on Lipoprotein(a): a call to action [J]. Atherosclerosis, 2019, 291: 62-70.
|
| 3 |
Kronenberg F, Mora S, Stroes E, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement [J]. Eur Heart J, 2022, 43(39): 3925-3946.
|
| 4 |
Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease: a review [J]. JAMA Cardiol, 2022, 7(7): 760-769.
|
| 5 |
Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study [J]. J Am Coll Cardiol, 2020, 76(25): 2982-3021.
|
| 6 |
Shi S, Tang Y, Zhao Q, et al. Prevalence and risk of atrial fibrillation in China: a national cross-sectional epidemiological study [J]. Lancet Reg Health West Pac, 2022, 23: 100439.
|
| 7 |
中华医学会心电生理和起搏分会, 中国医师协会心律学专业委员会, 中国房颤中心联盟心房颤动防治专家工作委员会. 心房颤动: 目前的认识和治疗建议(2021) [J]. 中华心律失常学杂志, 2022, 26(1): 15-88.
|
| 8 |
Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association [J]. Arterioscler Thromb Vasc Biol, 2022, 42(1): e48-e60.
|
| 9 |
Okura H, Inoue H, Tomon M, et al. Increased plasma lipoprotein(a) level in cardioembolic stroke with non-valvular atrial fibrillation [J]. Intern Med, 1998, 37(11): 995.
|
| 10 |
Igarashi Y, Yamaura M, Ito M, et al. Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: a transesophageal echocardiographic study [J]. Am Heart J, 1998, 136(6): 965-971.
|
| 11 |
殷运收. 脂蛋白(a)对老年心房颤动患者脑卒中危险关系的临床探讨 [J]. 临床荟萃, 2003, 18(14): 813-814.
|
| 12 |
Yan S, Li Q, Xia Z, et al. Risk factors of thromboembolism in nonvalvular atrial fibrillation patients with low CHA2DS2-VASc score [J]. Medicine (Baltimore), 2019, 98(8): e14549.
|
| 13 |
朱慎慎, 吴照科, 胡艳敏. Lp(a)对老年慢性心力衰竭患者发生心房颤动的预测价值 [J]. 中国循证心血管医学杂志, 2019, 11(2): 215-218.
|
| 14 |
Aronis KN, Zhao D, Hoogeveen RC, et al. Associations of lipoprotein(a) levels with incident atrial fibrillation and ischemic stroke: the ARIC (atherosclerosis risk in communities) study [J]. J Am Heart Assoc, 2017, 6(12): e007372.
|
| 15 |
Garg PK, Guan W, Karger AB, et al. Lp(a) (lipoprotein [a]) and risk for incident atrial fibrillation: multi-ethnic study of atherosclerosis [J]. Circ Arrhythm Electrophysiol, 2020, 13(5): e008401.
|
| 16 |
Mohammadi-Shemirani P, Chong M, Narula S, et al. Elevated lipoprotein(a) and risk of atrial fibrillation: an observational and mendelian randomization study [J]. J Am Coll Cardiol, 2022, 79(16): 1579-1590.
|
| 17 |
Jiang Q, Qin D, Yang L, et al. Causal effects of plasma lipids on the risk of atrial fibrillation: a multivariable mendelian randomization study [J]. Nutr Metab Cardiovasc Dis, 2021, 31(5): 1569-1578.
|
| 18 |
Song J, Zhang X, Wei M, et al. Association between lipoprotein(a) and thromboembolism in patients with non-valvular atrial fibrillation: a cross-sectional study [J]. Lipids Health Dis, 2022, 21(1): 78.
|
| 19 |
王海燕, 钟鹏, 白英. 脂蛋白a对心房颤动患者住院期间发生急性心肌梗死和卒中风险的影响 [J]. 中国医药, 2022, 17(7): 971-974.
|
| 20 |
Li Y, Chen L, Shao Y, et al. The effect of apolipoprotein E gene polymorphism and Lp(a) levels on coronary artery disease with atrial fibrillation [J]. J Int Med Res, 2022, 50(7): 3000605221109387.
|
| 21 |
Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality [J]. JAMA, 2009, 302(4): 412-423.
|
| 22 |
Zhao L, Tian X, Lu J, et al. Clinical application and comparison of serum lipoprotein (a) particle concentration and mass concentration in stroke patients and healthy adults: a prospective cohort study [J]. Ann Palliat Med, 2022, 11(12): 3704-3711.
|
| 23 |
Jiang X, Xu J, Hao X, et al. Elevated lipoprotein(a) and lipoprotein-associated phospholipase A(2) are associated with unfavorable functional outcomes in patients with ischemic stroke [J]. J Neuroinflammation, 2021, 18(1): 307.
|
| 24 |
Feng Z, Xu J, Jin A, et al. Elevated homocysteine intensify the effect of lipoprotein(a) on stroke recurrence [J]. J Am Heart Assoc, 2023, 12(1): e026707.
|
| 25 |
Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association [J]. J Clin Lipidol, 2019, 13(3): 374-392.
|
| 26 |
张智文, 杨海涛, 李牧蔚. 中性粒细胞与淋巴细胞比值在心房颤动中的应用价值 [J/OL]. 中华脑血管病杂志(电子版), 2022, 16(4): 236-240.
|
| 27 |
Boffa MB, Koschinsky ML. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease [J]. Nat Rev Cardiol, 2019, 16(5): 305-318.
|
| 28 |
Kim DS, Khandelwal A. Lipoprotein(a) and incident atrial fibrillation: leveraging nature's randomization to identify novel causal associations [J]. J Am Coll Cardiol, 2022, 79(16): 1591-1593.
|
| 29 |
Mehta A, Shapiro MD. Apolipoproteins in vascular biology and atherosclerotic disease [J]. Nat Rev Cardiol, 2022, 19(3): 168-179.
|
| 30 |
Ding WY, Protty MB, Davies IG, et al. Relationship between lipoproteins, thrombosis, and atrial fibrillation [J]. Cardiovasc Res, 2022, 118(3): 716-731.
|
| 31 |
北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议 [J]. 中国循环杂志, 2021, 36(12): 1158-1167.
|
| 32 |
O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk [J]. Circulation, 2019, 139(12): 1483-1492.
|
| 33 |
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome [J]. N Engl J Med, 2018, 379(22): 2097-2107.
|
| 34 |
Vogt A. Lipoprotein(a)-antisense therapy [J]. Clin Res CardiolSuppl, 2019, 14(Suppl 1): 51-56.
|
| 35 |
Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease [J]. N Engl J Med, 2020, 382(3): 244-255.
|
| 36 |
Lippi G, Favaloro EJ, Sanchis-Gomar F. Antisense lipoprotein[a] therapy: state-of-the-art and future perspectives [J]. Eur J Intern Med, 2020, 76: 8-13.
|
| 37 |
Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels [J]. JAMA, 2022, 327(17): 1679-1687.
|
| 38 |
Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a) [J]. Nat Med, 2022, 28(1): 96-103.
|